A Aralex Aachen research explorer

February 04, 2020 article Open access

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

British Journal of Haematology

DOI: 10.1111/bjh.16462 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 5 stored of 117

Primary Myelofibrosis ( PMF )—The German ONKOPEDIA Guideline 2025
2026 International Journal of Cancer article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

0

citations
Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
2025 European Journal Of Haematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

5

citations
A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
2023 Clinical Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

1

citations
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
2023 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

13

citations
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
2022 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access

11

citations

5 results

References 0